BioPharma Resources

Drug Trial Radar · NCT05486104

Phase II Study of Hemay005 in Patients With Active Ulcerative Colitis

A Multicenter, Randomized, Double-blind, Placebo Parallel Controlled Clinical Study on the Effecacy and Safety of Low-High Dosing Regimens of Hemay005 in Patients With Moderate to Severe Ulcerative Colitis

Last checked: Nov 19, 2026Latest source record: Apr 3, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruiting

Status

Active, not recruiting

Enrollment

92

Actual

Start

Nov 8, 2022

Primary completion

Dec 30, 2026

Study completion Dec 30, 2026

Sponsor

Sponsor type
Industry
First posted
Aug 3, 2022

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study is a multicenter, randomized, double-blind study. There are three dosage groups: Hemay005 45 mg BID group, 60 mg BID group or placebo group, with 36 patients in each dosage group. All patients will enter a 12-week double-blind treatment period. All subjects who have received the investigational drug should be subjected to a 4-week observation after the end of treatment.

Conditions

  • Moderate to Severe Ulcerative Colitis

Interventions

  • Hemay005 tabletsDrug

    Hemay005 tablets (15mg/tablet)will be orally administered twice daily.

  • Hemay005 placebo tabletsDrug

    Hemay005 placebo tablets will be orally administered twice daily.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. clinical remissionTime frame: 12 week

Locations

18 sites in 1 country. Site status is shown where the registry gives one.

  • Beijing Chaoyang Hospital Affiliated to Capital Medical University

    Beijing, China

  • Beijing Friendship Hospital Affiliated to Capital Medical University

    Beijing, China

  • Peking University Third Hospital

    Beijing, China

  • Chongqing People's Hospital

    Chongqing, China

  • Shanghai Oriental Hospital

    Shanghai, China

  • Tianjin Medical University General Hospital

    Tianjin, China

  • The Fourth Affiliated Hospital of Anhui Medical University

    Hefei, Anhui, China

  • The First Affiliated Hospital of Fujian Medical University

    Fuzhou, Fujian, China

  • The Second Affiliated Hospital of Guangzhou Medical University

    Guangzhou, Guangdong, China

  • First Affiliated Hospital of Zhengzhou University

    Zhengzhou, Henan, China

  • Union Hospital Affiliated to Tongji Medical College, Huazhong University of Science and Technology

    Wuhan, Hubei, China

  • Xiangya Hospital of Central South University

    Changsha, Hunan, China

  • The First Affiliated Hospital of Nanchang University

    Nanchang, Jiangxi, China

  • Shengjing Hospital Affiliated to China Medical University

    Shenyang, Liaoning, China

  • Qilu Hospital of Shandong University

    Jinan, Shandong, China

  • Shandong Provincial Hospital

    Jinan, Shandong, China

  • Sichuan Provincial People's Hospital

    Chengdu, Sichuan, China

  • First Affiliated Hospital of Zhejiang University School of Medicine

    Hangzhou, Zhejiang, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.